Proximagen Group proximagen.com


Public list: BIO 2016 (619) Pharma Startups (4733)

Proximagen Group (AIM: PRX) is a biotechnology company focused on the development and commercialization of therapeutics for diseases of the central nervous system and inflammation.

Proximagen Group (AIM: PRX) is a biotechnology company focused on the development and commercialization of therapeutics for diseases of the central nervous system and inflammation.

Company (Acquired)

Phone: +44(0)20 7400 7700

Fax: +44(0)20 7831 5387

3rd Floor
91-93 Farringdon Rd
London, EC1M 3LN
England, United Kingdom

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Proximagen Group $0M Aug 14, 2012

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Proximagen Group Jobs

jobs by Indeed job
						search
There is no Board of Directors data available for this company. Please select another tab.
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as ssao inhibitors May 11, 2017 Apr 24, 2018 Patent
Compounds i Oct 27, 2016 Feb 13, 2018 Patent
Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as ssao inhibitors Mar 13, 2014 Jun 13, 2017 Patent
Compounds Mar 13, 2014 Feb 28, 2017 Patent
Substituted imidazo[4,5-c]pyridine compounds and compositions thereof Mar 13, 2014 Aug 30, 2016 Patent
See all 23 patents